Chemotherapy Every 3 Weeks Seen as Effective as Weekly Dosing in European Ovarian Cancer Patients

Chemotherapy Every 3 Weeks Seen as Effective as Weekly Dosing in European Ovarian Cancer Patients
Researchers compared weekly doses of Taxol (paclitaxel) to treat ovarian cancer with dosing every three weeks in a European trial to determine if weekly dosing was more effective. They found that weekly dosing did not extend progression-free survival (PFS) in this patient population. The results were surprising because an earlier Japanese trial, JGOG3016 (NCT00226915), had shown that weekly dosing was more effective than dosing every three weeks. Researchers are attributing the difference in results to genetic differences between Caucasians and Asians. The results of the ICON8 Phase 3 trial (NCT01654146) were highlighted in the poster, "ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression-free survival (PFS) analysis," presented at the European Society for Medical Oncology (ESMO) 2017 Congress. The purpose of the trial was to determine if weekly chemotherapy to treat ovarian cancer by giving Taxol and Paraplatin (carboplatin) at a lower dose every week is more effective than the standard chemotherapy regimen of Taxol and Paraplatin give
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *